Jincheng Pharmaceutical: Announcement on the Subsidiary’s Receipt of Approval Notice for Drug Supplementary Application
Securities code: 300233 Securities abbreviation: Jincheng Pharmaceutical Announcement number: 2026-002
Shandong Jincheng Pharmaceutical Group Co., Ltd.
Announcement on the Subsidiary’s Receipt of Approval Notice for Drug Supplementary Application
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and that there are no false records, misleading statements or major omissions.
Guangdong Jincheng Jinsu Pharmaceutical Co., Ltd. (hereinafter referred to as "Jincheng Jinsu"), a holding subsidiary of Shandong Jincheng Pharmaceutical Group Co., Ltd., recently received the "Drug Supplementary Application Approval Notice" for cefuroxime sodium for injection issued by the National Medical Products Administration. The main contents are now announced as follows:
1. Basic information on drugs
Listing permission
Product Registration Packaging Original Drug Batch Production
Specifications Can be held Approval conclusion
Name Type Classification Specification Quarantine Number Enterprise
people
According to the "National Drug Approval of the People's Republic of China"
0.5g Drug Administration Law and related regulations H20065669
(1) It is determined that after review, this product is
The application matters for each box comply with the requirements for drug registration.
Note 0.75 for 1 bottle. According to the relevant requirements of the National Drug Approval, this product is approved Chemistry Jincheng Jincheng
g (2) H20065670 Changes in registration standards. quality spores medicine gold gold gold
The dosage per box shall be as per the attached standard. Other furans
- Execute as originally approved. Xiangxin
bottle. National Drug Approval: Changes should be made from the date of approval. Sodium 1.5g
H20065672 will be implemented within 6 months.
2. Drug related information
Cefuroxime Sodium for Injection is a localized product of the company's original drug (reference preparation) (trademark: Revlux), which is directly packaged and produced using ACSDOBFARS.P.A technology and raw materials. This drug is mainly suitable for the following infections caused by bacteria that are sensitive to cefuroxime: respiratory tract and ear, nose and throat infections; urinary tract infections; skin and soft tissue infections; sepsis; meningitis; bone and joint infections, etc. In addition, this product can be used to prevent infection before or during surgical operations, such as abdominal, pelvic, orthopedic, heart, lung, esophageal, vascular and total joint replacement operations.
3. Impact on the company and risk warning
This revision of the quality standards for Jinchengjinsu Cefuroxime Sodium for Injection has positive significance for improving its product quality. Pharmaceutical sales are affected by uncertain factors such as national policies and market environment. Investors are advised to pay attention to risks and invest rationally.
Announcement is hereby made.
Board of Directors of Shandong Jincheng Pharmaceutical Group Co., Ltd.
January 21, 2026